2Bradshaw C,Kakar SS. Pituitary tumor transforming gene:an im-portant gene in normal cellular functions and tumorigenesis[J].{H}Histology and Histopathology,2007,(02):219-222. 被引量：1
3Davis JR,Mcheilly AS. Is pituitary gene therapy realistic[J].Clin En-docrinol,2001,(04):427-433. 被引量：1
8Fiorent ini C,Guerra N,Facchet ti M. Nerve growth factor regulates dopamine D (2) receptor expression in prolactinoma cell-lines via p75 (NGFR) mediated activation of nuclear fact or kap paB[J].{H}Molecular Endocrinology,2002,(02):353. 被引量：1
9Zhou G,Mihindukulasuri ya KA,MacCorkle Chosnek RA. Protei n phosphatase 4 is invol ved in tumor necrosis fact or alpha induced activation of c Jun Nterminal kinase[J].{H}Journal of Biological Chemistry,2002,(08):6391. 被引量：1
10Hu MC,Tang Oxley Q,Qiu WR. Prot ein phosphatase X interacts with Rel and stimulat esc Rel nuclear fact or kappa B ac-tivit y[J].{H}Journal of Biological Chemistry,1998,(50):33561. 被引量：1
10[3]Harding TC, Geddes B J, Murphy D, et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system [J]. Nat Biotechnol, 1998; 16(6): 553-555. 被引量：1
4Cho KR,Jo KI,Shin HJ.Bromocriptine Therapy for the treatment of invasive prolactinoma:the single institute experience [J]. Brain Tumor Res Treat,2013,1 (2) :71-77. 被引量：1
5Dos Santos Nunes V,E1 Dib R,Boguszewski CL,et al. Cabergo- line versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta- analysis[J].Pituitary, 2011,14 ( 3 ) : 259-265. 被引量：1
6Di Sarno A,Landi ML,Cappabianca P,et al. Resistance to caber- goline as compared with bromocriptine in hyperprelactinemia: prevalence, clinical definition ,and therapeutic strategy[J]. J Clin Endocrinol bietab, 2001,86 ( 11 ) : 5256-5261. 被引量：1
8Auriemma RS,Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas[J].Eur J Endocrinol, 2013,169 ( 3 ) : 359-366. 被引量：1
9Dhawan V,Medcalf P,Stegie F,et al. Ray chaudhuri, retrospec- tive evaluation of cardio-pulmonary fibrotic side effects in symp- tom-atic patients from a group of 234 Parkinsen's disease pa- tients treated with cabergoline[J]. J Neural Transm,2005,112(5 ) : 661-668. 被引量：1
10Shimazu S,Shimatsu A,Yamada S,et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels [J]. Eur J Endocfinol,2012,166(3):383-390. 被引量：1
